In a small trial, Mass General Brigham researchers have found that a drug designed to treat celiac disease supported a more rapid return to normal activities for patients following COVID. New research ...

Multisystem inflammatory syndromes in children represent a rare but serious post-infectious hyperinflammatory condition most notably observed in association with SARS-CoV-2. Clinically, affected ...

MIS-C is a serious inflammatory shock that affects children. It can occur several weeks after a COVID infection and can be life-threatening. Until now, however, the precise cause of the condition was ...

Larazotide, an oral drug, may effectively treat MIS-C by tightening the gut epithelial barrier, reducing systemic inflammation. The phase 2a trial showed faster resolution of GI symptoms and spike ...

Faster resolution of GI symptoms, faster clearance of spike antigen, faster return to usual activities reported for children treated with larazotide. HealthDay News — Treatment of multisystem ...

Multisystem inflammatory syndrome in children (MIS-C), a serious disorder that develops after SARS-CoV-2 infection, could arise from latent infection of another pathogen, the Epstein-Barr virus (EBV).

Why are some children devastated by mysterious post-COVID inflammation? Scientists uncover how a ‘silent’ virus awakens – and a promising path to stop it. Study: TGFβ links EBV to multisystem ...

HS is now viewed as a multisystem inflammatory disease, requiring comprehensive management beyond dermatologic treatment. Genetic links, such as increased HS risk in trisomy 21, highlight the need for ...